Abbott Laboratories $ABT Shares Sold by Border to Coast Pensions Partnership Ltd

Key Points

• Border to Coast Pensions Partnership Ltd cut its Abbott stake by 14.0%, selling 59,329 shares and leaving it with 363,027 shares valued at about $45.57 million.
• Director Daniel J. Starks purchased 10,000 shares at an average $108.73, while insiders collectively sold 3,055 shares in the quarter; company insiders now own 0.46% of the stock.
• Abbott reported quarterly EPS of $1.50 (in line with estimates) and $11.46 billion in revenue (slightly below consensus), and issued guidance of Q1 2026 EPS 1.120–1.180 and FY 2026 EPS 5.550–5.800.

Border to Coast Pensions Partnership Ltd lowered its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 14.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 363,027 shares of the healthcare product maker's stock after selling 59,329 shares during the quarter. Border to Coast Pensions Partnership Ltd's holdings in Abbott Laboratories were worth $45,566,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $101.55 on Thursday. Abbott Laboratories has a 12 month low of $99.05 and a 12 month high of $139.06. The company has a market cap of $176.86 billion, a PE ratio of 27.30, a P/E/G ratio of 1.61 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The company has a fifty day moving average price of $108.45 and a two-hundred day moving average price of $119.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company's revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories's payout ratio is 67.74%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Daiwa Securities Group decreased their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an "outperform" rating for the company in a report on Friday, January 30th. Freedom Capital raised shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 29th. Barclays lifted their price objective on shares of Abbott Laboratories from $142.00 to $144.00 and gave the stock an "overweight" rating in a report on Wednesday, April 8th. BTIG Research decreased their price objective on shares of Abbott Laboratories from $140.00 to $131.00 and set a "buy" rating for the company in a report on Tuesday, March 31st. Finally, Citigroup decreased their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a "buy" rating for the company in a report on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus target price of $134.58.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.